Table 1.
Characteristics of the study population.
| Variable | All n (%) or mean (SD) (N=6,500) |
|---|---|
| Outcome | |
| Cancer death | 996 (15.3%) |
| CV event | 328 (5.1%) |
| Death (other cause) | 542 (8.3%) |
| Censoreda (<1 year) | 241 (3.7%) |
| Censoreda (1–5 years) | 2,499 (38.5%) |
| Censoreda (>5 years) | 1,894 (29.1%) |
| Year of diagnosis | |
| 2001 | 659 (10.1%) |
| 2002 | 726 (11.2%) |
| 2003 | 789 (12.1%) |
| 2004 | 713 (11.0%) |
| 2005 | 815 (12.5%) |
| 2006 | 878 (13.5%) |
| 2007 | 998 (15.4%) |
| 2008 | 922 (14.2%) |
| Age at diagnosis | 66.7 (11.5) |
| Sex | |
| Male | 3,225 (49.6%) |
| Female | 3,275 (50.4%) |
| Low SES | 882 (13.6%) |
| Previous CV diagnosis | 1,875 (28.8%) |
| Cancer site | |
| Bladder | 431 (6.6%) |
| Breast | 1,451 (22.3%) |
| Colon | 788 (12.1%) |
| Endometrium | 216 (3.3%) |
| Head and neck | 241 (3.7%) |
| Kidney and renal pelvis | 207 (3.2%) |
| Lung | 184 (2.8%) |
| Non-Hodgkin lymphoma | 397 (6.1%) |
| Prostate | 1,349 (20.8%) |
| Skin melanoma | 437 (6.7%) |
| Other | 799 (12.3%) |
| On statin at diagnosis | 2,136 (32.9%) |
| SEER 5-year survival | |
| 26–50% | 802 (12.3%) |
| 51–75% | 1,087 (16.7%) |
| 76–100% | 4,611 (70.9%) |
| Other morbidityb (number of conditions) | |
| 0 | 3,209 (49.4%) |
| 1 | 1,822 (28.0%) |
| ≥2 | 1,469 (22.6%) |
| Diabetes at baseline | 1,243 (19.1%) |
| Baseline smoking status (ever/never) | 1,005 (15.5%) |
| Baseline systolic BP | 132.2 (18.8) |
BP, blood pressure; CV, cardiovascular; SD, standard deviation; SEER, Survival, Epidemiology, and End Results; SES, socioeconomic status.
aCensored refers to disenrollment from the health plan, or reaching the end date of the observation period without an event (December 31, 2010).
bModified Charlson Comorbidity Index (excludes cancer and cardiovascular morbidity).